Vanda Pharmaceuticals Reports Mixed Q2 2026 Results Amid Pipeline Advancements — Vanda Pharmaceuticals Inc.

Event summary

Fanapt® net product sales increased 23% year-over-year to $36.0 million in Q2 2026.
Total net product sales decreased 4% year-over-year to $50.5 million in Q2 2026, excluding deferred HETLIOZ® revenue.
BYSANTI™ received FDA approval for bipolar I disorder and schizophrenia in Q1 2026, with commercial launch expected in the second half of 2026.
Quimilza™ BLA under review by the FDA with a PDUFA target action date of December 12, 2026.
Cash totaled $170.0 million as of June 30, 2026, expected to fund operations through at least the end of 2027.

The big picture

Vanda Pharmaceuticals is navigating a period of significant investment in pipeline development and commercial expansion, with multiple regulatory and clinical milestones on the horizon. The company's ability to balance these growth initiatives with cost management will be crucial as it aims to sustain momentum in its core products while advancing new therapies. The strategic focus on high-unmet medical needs positions Vanda within broader industry trends toward specialized therapeutic solutions.

What we're watching

Commercial Execution: The pace at which Vanda can successfully launch BYSANTI™ and scale NEREUS™ sales will be critical to meeting revenue guidance.
Regulatory Milestones: Whether the FDA approves Quimilza™ by the December 12, 2026 PDUFA date and the outcomes of late-stage clinical trials for NEREUS™, VQW-765, and HETLIOZ®.
Cost Management: How effectively Vanda moderates operating expenses as Phase III programs and launch preparations near completion.